ID   M019iCis
AC   CVCL_JM65
DR   PRIDE; PXD002394
DR   Wikidata; Q54903412
RX   PubMed=28455291;
RX   PubMed=28473707;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_JM64 ! M019i
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 22-08-17; Last updated: 19-12-24; Version: 6
//
RX   PubMed=28455291; DOI=10.1074/mcp.M116.058321; PMCID=PMC5500768;
RA   Nguyen E.V., Huhtinen K., Goo Y.A., Kaipio K., Andersson N.,
RA   Rantanen V., Hynninen J., Lahesmaa R., Carpen O., Goodlett D.R.;
RT   "Hyper-phosphorylation of sequestosome-1 distinguishes resistance to
RT   cisplatin in patient derived high grade serous ovarian cancer
RT   cells.";
RL   Mol. Cell. Proteomics 16:1377-1392(2017).
//
RX   PubMed=28473707; DOI=10.1038/s41598-017-01624-4; PMCID=PMC5431431;
RA   Lund R.J., Huhtinen K., Salmi J., Rantala J., Nguyen E.V., Moulder R.,
RA   Goodlett D.R., Lahesmaa R., Carpen O.;
RT   "DNa methylation and transcriptome changes associated with cisplatin
RT   resistance in ovarian cancer.";
RL   Sci. Rep. 7:1469-1469(2017).
//